Brain

ALLT.AI unveils the next generation of Large Language Models (LLMs) driven by the remarkable power and efficiency of the human brain

Translating decades of clinical neuroscience research into next-generation AI—ALLT.AI harnesses key data from damaged brains to create radically more efficient…

3 months ago

Aoki Games & Gala 2025 Returns to Las Vegas Sunday, September 21

Live performance, visionary conversations, and a tribute to Ray Kurzweil unite in support of brain health and innovation. LAS VEGAS,…

3 months ago

Apollo Biowellness, Inc., to Merge with Revive Regenerative, Inc.

North Bergen, New Jersey--(Newsfile Corp. - September 17, 2025) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company") is pleased to…

3 months ago

NovalGen to Begin World’s First Clinical Trial for a Self-Regulating Immunotherapy

LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The world’s first therapeutic drug to be equipped with NovalGen’s pioneering AutoRegulation (AR)…

3 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA ApprovalKANSAS CITY, Kan., Sept. 17, 2025 (GLOBE NEWSWIRE)…

3 months ago

New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)

Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) servicesMALVERN, Pa., Sept. 17, 2025…

3 months ago

Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to…

3 months ago

Omni-Biotic US Expands Into Children’s Gut Health With Two New Probiotics: AB 10 Kids and Stress Release Kids

NEW YORK CITY, NEW YORK / ACCESS Newswire / September 17, 2025 / Omni-Biotic US, the company that introduced Europe's…

3 months ago

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational…

3 months ago

AskBio Announces Completion of Enrollment in Phase 1 Clinical Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)

Research Triangle Park, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Final participant randomized to complete enrollment in Phase 1 clinical…

3 months ago